The device is ingested similar to other existing capsule endoscopic devices in accordance with current clinical practice. Once the device is initiated, it will start detecting immediately using optical technology and can be used to monitor the presence of UGIB for a period up to 3 days. The data is wirelessly transmitted to an external monitor (PC, mobile phone, custom receiver, etc.) enabling a real-time diagnosis.
The IP was originally developed in Harvard University and was enhanced by the EnteraSense team.
It will alleviate the need for patients to undergo unnecessary procedures and ensure prompt diagnoses and correct treatment. With a potential reduction of unnecessary endoscopies, the Health Economics benefits to the hospital and insurance companies are significant.
Potential market in excess of $1bn
This product addresses UGIB both as an inpatient and in a triage setting. Today in the United States 1.1M patients attend ER for suspected bleeding but only two thirds of them are diagnosed with actual bleeding. This device offers a solution for the emergency room to triage patients more efficiently. Additionally, of the patients hospitalised with UGIB, a high percentage are high-risk and require monitoring after treatment. This device offers a unique solution for real-time monitoring of these patients for up to 3 days.
The total market potential for this product in Europe and in the United States is $1.6B.